The COVID-19 pandemic has created a rise in demand for contract organizations.

Extra Hands Fight Pandemic

Cellular and gene therapy fields are currently on track for a serious capacity crunch.

Manufacturing Capacity Crunch

Topic

Articles

3P Biopharmaceuticals, and Oxford University spin-out, SpyBiotech, have signed a vaccine contract manufacturing agreement.

3P Biopharmaceuticals and SpyBiotech Sign Vaccine Manufacturing Agreement

Catalent has signed an agreement with Bone Therapeutics for the acquisition of Skeletal Cell Therapy Support SA (SCTS).

Catalent Acquires Bone Therapeutics’ Cell Manufacturing Facility 

Following a recent expansion at its Cambridge, MA, facility, the company now houses a new suite of cellular analysis platforms that enhance its exploratory capabilities into oncology, neuroscience, and rare diseases.

Sai Life Sciences’ Screening Capabilities Enhanced with Expanded Cellular Analysis Platforms

The company’s new CytoML Experiment Suite fully automates each stage of the flow cytometry data lifecycle, allowing for clearer data visualization and analysis.

Aigenpulse’s Data Analysis Suite Automates Flow Cytometry

GRAM is expanding fill/finish capacity and is working with Janssen on tech transfer in preparation for production of Janssen’s SARS-CoV-2 vaccine candidate at GRAM’s Grand Rapids, MI facility. 

GRAM Partners with Johnson & Johnson for Fill/Finish of Vaccine Candidate

The investment at its Madison, WI, facility will expand MilliporeSigma’s capacity for high-potent active pharmaceutical ingredient production and allow for continuous flow manufacturing of ADCs.

MilliporeSigma Invests $65 Million to Expand Antibody-Drug Conjugate Manufacturing

The company is investing $130 million to add Phase III through commercial-scale manufacturing suites to its gene therapy campus in Harmans, MD.

Catalent Invests $130 Million to Expand Gene Therapy Manufacturing Capacity

Jennifer Markarian is manufacturing editor of Pharmaceutical Technology.

Rapid scale-up to billions of doses requires collaborative, all-out efforts by innovators, their manufacturing partners, and the entire supply chain. 

Preparing Pandemic Vaccine Capacity

Ronald A. Rader is senior director, Technical Research, at BioPlan Associates.

Cellular and gene therapy fields are currently on track for, if not already experiencing, a serious capacity crunch. 

Cellular and Gene Therapies Face a Manufacturing Capacity Crunch

Thermo Fisher Scientific is increasing access to cry-electron microscopy with the help of contract research organizations.

Outsourcing

Extra Hands Fight Pandemic

Manufacturing Capacity Crunch